Overview of the Allergy Immunotherapies Market

Over the years, the allergy immunotherapies market has grown significantly owing to rising allergic conditions such as asthma, allergic rhinitis, and food allergies. A promising long-term relief has emerged with immunotherapy, especially by employing techniques such as SCIT and SLIT. The market was projected at US$ 2.16 Bn in 2021 and US$ xx Bn in 2023. It is expected to reach US$ 5.11 Bn by 2031 and record a CAGR of 9.0% till 2031.

Key Drivers

1. Increased Incidence of Allergies: The increased incidence of allergic diseases globally due to changes in the environment and lifestyle has raised a demand for better treatment modalities.
2. Improvements in Immunotherapy: Advancement through research and development has improved the efficacy and safety profiles of immunotherapies, thus making them more attractive both to healthcare providers and patients.
3. Awareness and Education: Increased awareness of the benefits of immunotherapy compared to traditional medications has encouraged more patients to seek these treatments.